Is an AI-Designed Drug Any Different? | Dalton TX

Is AI really changing drug discovery yet, or is it mostly hype? Two founders give a straight answer. Amber Hayes of The BioHub talks to Dr Garry Pairaudeau, Co-Founder and CEO, and Dr Anthony Bradley, Co-Founder and Chief Scientific Officer of Dalton Tx. Garry and Anthony worked together at Exscientia before founding Dalton Tx in London. They talk about how they came to AI drug discovery, what separates meaningful progress from hype, why partnerships with biotechs and CROs keep them honest, and what they hope the next five to ten years will bring. In this episode: • How a chemist and a computational chemist found their way into AI drug discovery • Why Dalton Tx is building a new operating system for drug discovery • Where AI is, and is not, having an impact today • Why experimental validation is the test of meaningful progress • Why combining software engineering, AI and drug discovery expertise matters • Building a team and an office-based culture as first-time founders • Two misconceptions about AI drug discovery • World models and the future of AI-enabled discovery Learn more: https://daltontx.com/ and www.avetixgroup.com Chapters 00:00 Coming up 00:41 Introduction 01:38 Garry's route into AI drug discovery 03:29 Anthony's background in computation 05:02 The decision to found Dalton Tx 08:50 What Dalton Tx is building 10:43 Where AI is having impact today 13:08 Meaningful progress versus hype 15:47 Lessons from partnerships 17:51 Combining engineering, AI and drug discovery 20:20 Building the team and culture 24:19 Misconceptions about AI drug discovery 26:49 The future of AI-enabled discovery 29:14 Dinner with an innovator https://daltontx.com/ www.avetixgroup.com #AIDrugDiscovery #DaltonTx #BioHubPodcast